TuisBSX • NYSE
add
Boston Scientific Corp
Vorige sluiting
$104,34
Dagwisseling
$102,48 - $104,43
Jaarwisseling
$80,64 - $109,50
Markkapitalisasie
152,19 mjd USD
Gemiddelde volume
6,27 m
P/V-verhouding
61,15
Dividend-opbrengs
-
Primêre beurs
NYSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Jun. 2025info | J/J-verandering |
---|---|---|
Inkomste | 5,06 mjd | 22,84% |
Bedryfskoste | 2,47 mjd | 20,81% |
Netto inkomste | 797,00 m | 145,99% |
Netto winsgrens | 15,75 | 100,38% |
Wins per aandeel | 0,75 | 20,97% |
EBITDA | 1,28 mjd | 15,23% |
Effektiewe belastingkoers | 15,52% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Jun. 2025info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 534,00 m | -81,67% |
Totale bates | 41,56 mjd | 11,99% |
Totale aanspreeklikheid | 18,91 mjd | 14,59% |
Totale ekwiteit | 22,65 mjd | — |
Uitstaande aandele | 1,48 mjd | — |
Prys om te bespreek | 6,89 | — |
Opbrengs op bates | 5,77% | — |
Opbrengs op kapitaal | 6,85% | — |
Kontantvloei
Netto kontantverandering
(USD) | Jun. 2025info | J/J-verandering |
---|---|---|
Netto inkomste | 797,00 m | 145,99% |
Kontant van bedrywe | 1,29 mjd | 58,18% |
Kontant van beleggings | -1,13 mjd | -315,50% |
Kontant van finansiering | -340,00 m | -1 516,67% |
Netto kontantverandering | -178,00 m | -131,45% |
Beskikbare kontantvloei | 1,16 mjd | 111,56% |
Meer oor
Boston Scientific Corporation, is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator.
Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
Gestig
29 Jun. 1979
Webwerf
Werknemers
53 000